High-throughput screen with the l,d-transpeptidase LdtMt2 of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors

Disruption of bacterial cell wall biosynthesis in Mycobacterium tuberculosis is a promising target for treating tuberculosis. The l,d-transpeptidase LdtMt2, which is responsible for the formation of 3 → 3 cross-links in the cell wall peptidoglycan, has been identified as essential for M. tuberculosi...

Full description

Saved in:
Bibliographic Details
Published inChemical science (Cambridge) Vol. 14; no. 26; pp. 7262 - 7278
Main Authors de Munnik, Mariska, Lang, Pauline A, De Dios Anton, Francisco, Cacho, Mónica, Bates, Robert H, Brem, Jürgen, Beatriz Rodríguez Miquel, Schofield, Christopher J
Format Journal Article
LanguageEnglish
Published Cambridge Royal Society of Chemistry 05.07.2023
The Royal Society of Chemistry
Subjects
Online AccessGet full text
ISSN2041-6520
2041-6539
DOI10.1039/d2sc06858c

Cover

More Information
Summary:Disruption of bacterial cell wall biosynthesis in Mycobacterium tuberculosis is a promising target for treating tuberculosis. The l,d-transpeptidase LdtMt2, which is responsible for the formation of 3 → 3 cross-links in the cell wall peptidoglycan, has been identified as essential for M. tuberculosis virulence. We optimised a high-throughput assay for LdtMt2, and screened a targeted library of ∼10 000 electrophilic compounds. Potent inhibitor classes were identified, including established (e.g., β-lactams) and unexplored covalently reacting electrophilic groups (e.g., cyanamides). Protein-observed mass spectrometric studies reveal most classes to react covalently and irreversibly with the LdtMt2 catalytic cysteine (Cys354). Crystallographic analyses of seven representative inhibitors reveal induced fit involving a loop enclosing the LdtMt2 active site. Several of the identified compounds have a bactericidal effect on M. tuberculosis within macrophages, one with an MIC50 value of ∼1 μM. The results provide leads for the development of new covalently reaction inhibitors of LdtMt2 and other nucleophilic cysteine enzymes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Present address: Janssen Research & Development, Janssen Pharmaceutica, B-2340 Beerse, Belgium.
ISSN:2041-6520
2041-6539
DOI:10.1039/d2sc06858c